Program

Oct. 16-17, 2024, Wyndham Philadelphia Historic District.

Ready to Register?

Register now!

Program

Already registered? 

Log into the virtual platform

Wednesday, Oct. 16

Registration, Poster Check In, Breakfast
7:30 – 8:30 a.m. 

Poster Abstract Sessions
8 a.m. – 6:45 p.m.; Poster Hall - FDR Ballroom

• 11. Lentiviral Vector-based Polymeric Nanoparticles as Gene and Cell Therapy Product - A cross-functional Approach to Streamline and Control a Complex Manufacturing Process 
  Cecile Bauche, PhD, Alaya.bio
• 12. Towards Off-the-Shelf CAR-T Therapy: Lentiviral Vector-based Polymeric Nanoparticles for In Situ Gene Delivery into T-cells for Haematological Malignancies & Beyond 
  Cecile Bauche, PhD, Alaya.bio 
• 13. An Optimal Pairing of scFv and Costimulatory Domain Regulates Dual CAR T Cell Signaling for Better Response Against B-ALL 
  Divanshu Shukla, PhD, University of Pennsylvania 
• (Virtual) 15. Bone-Marrow-Homing Lipid Nanoparticles for Genome Editing in Leukemia and Leukemic Stem Cells 
  Xizhen Lian, Johns Hopkins University 
• (Virtual) 16. A Novel Virus-Free Platform for Engineering CAR-T Cells with Enhanced Clinical Safety and Therapeutic Efficacy in Acute Lymphoblastic Leukemia 
  Philip Chiu-Tsun TANG, PhD, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong 
• (Virtual) 17. Efficient Combinatorial Adaptor-Mediated Targeting of Acute Myeloid Leukemia with CAR T-Cells 
  Laura Volta, PhD, University of Zurich Faculty of Medicine
• 18. Human Cord Blood-Derived Induced Pluripotent Stem Cells into Natural Killer Cells for Advanced Cancer Immunotherapy 
  Ranran Zhang, PhD, Catalent Cell and Gene Therapy
• 19. A Dual-Population CART Product for Safe and Effective Targeting of T-cell Malignancies 
  Ruchi Patel, PhD, Vittoria Biotherapeutics 
• 20. The Simultaneous Measurement of Edit Associated Structural Variation and Transgene Localization in Single Cells 
  Christopher Tompkins, PhD, KromaTiD
• 21. Zip-Code Delivery: Creation of a Novel Nucleic Acid based Targeted Delivery System
  Anthony Johnson, Kodikaz
• 22. INTASYL PH-894: Targeting BRD4 to Enhance NK Cell-Based Immunotherapy 
  Melissa Maxwell, Phio Pharmaceuticals  

Poster Abstract Sessions
8 a.m. – 6:45 p.m.; Poster Hall - Betsy Ross Ballroom

• 23. Therapeutic Targeting of the CBS-CD73 Signaling Axis Attenuates Head and Neck Cancer Progression
  Yong Teng, PhD, Emory University School of Medicine
• (Virtual) 24. mRNA-mediated Rescue of Lost Tumor Suppressor Function in Mutated p53 or BRCA1 Tumors is a Potent New Strategy for Cancer Therapy Delivered with Tumor-Targeted Peptide (non-LNP) Nanoparticles
  Neil Desai, Aanastra Inc
• (Virtual) 25. In Vivo CRISPR Gene Editing of KRAS Mutant Tumors with Tumor-Targeted (non-LNP) Peptide-based Nanoparticles Causes Strong Tumor Regressions with Only 2 Doses and Overcomes Resistance to Existing Small-Molecule KRAS Inhibitors
  Gilles Divita, PhD, DIVINCELL
• 26. Characterization and Preclinical Development of Tumor-Specific CRISPR/Cas9 Editing as a Combinatorial Therapy for Treatment-Resistant Solid Tumors 
  Kelly Banas, PhD, ChristianaCare 
• 27. Focused Ultrasound Mediated Thermogenetic Control of CAR T Cell Activity in Breast Cancer Brain Metastasis 
  Chulyong Kim, Georgia Institute of Technology 
• 28. Dual-targeting CD133/PD-L1 CAR-T Overcame Suppressive Microenvironment in Solid Tumor and Synergized with Radiotherapy and PD-1 Blockade 
  Kai Kang, MD, West China Hospital
• 29. A Platform for the Development of Personalized Oncolytic Adenoviruses
  Fred Bunz, MD, PhD, Johns Hopkins University School of Medicine
• 30. Controlled, Riboswitch-Regulated Gene and Cell Therapy Targeting HER2+ Tumors 
  Xuecui Guo, MeiraGTx 
• 31. Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs 
  Dolores Schendel, PhD, Medigene AG 
• 32. T Cell Immune Characterization of the h-Met ß-Catenin Sleeping Beauty Model of HCC and its Therapeutic Response to Immune Checkpoint Blockade 
  Thanich Sangsuwannukul, PhD, Mayo Clinic 
• (Virtual) 33. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Ramucirumab Clinical Trials 
  Adam Khan, Oklahoma State University 
• (Virtual) 34. Single Cell Bioinformatics Uncovers a Novel T Cell Origin as Effective Immunotherapy for Solid Tumors 
  Max Kam-Kwan Chan, Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong 
• (Virtual) 35. In Vitro and In Vivo Lipid Nanocrystal (LNC) Delivery of Small Oligonucleotides and Small Molecules in Oncology
  James Ferguson, MD, Matinas BioPharma
• 36. C/EBPß Drives Tumor Growth, Chemoresistance, and Immune Evasion Through the Stabilization of Senescent Secretory Cell Populations in the Tumor
  Kevin Holm, City of Hope Beckman Research Institute
• 37. Addressing the HEK293 Host Cell Protein Monitoring Challenges for Viral Vector Gene Therapy Manufacturing 
  Olivia Kelada, Revvity Inc 
• (Virtual) 38. A Novel Therapeutic Target of MDSC-dependent Immunosuppression in NSCLC 
  Siu Fan Jane Li, The Chinese University of Hong Kong 

Welcome, Opening Remarks
8:30 – 8:35 a.m. 

New Cancer-specific Antigens and Targeting of Intracellular Oncoproteins
8:35 – 10:20 a.m. 

• New cancer-specific antigens and targeting of intracellular oncoproteins, CAR-based
  Daniel Powell, PhD, University of Pennsylvania
• CAR T cell persistence - Balancing function and safety
  Nayan Jain, PhD, Memorial Sloan Kettering Cancer Center
• Panel Discussion + Q&A

Break (Paid Presentation by Emit Imaging)
10:30 – 10:45 a.m. 

Keynote Presentation
The Future of CAR-T Cells in Solid Tumors: Lessons Learned from Targeting Lymphoma
10:50 – 11:50 a.m.

• Barbara Savoldo, MD, PhD, University of North Carolina at Chapel Hill 

Lunch + Exhibits
11:50 a.m. – 12:50 p.m. 

Rational Combinations with Genetically Engineered Cells
12:55 – 2:10 p.m.  

• A synthetic booster vaccine for chimeric antigen receptor T cells
  Leyuan Ma, PhD, University of Pennsylvania
• Oncolytic viruses in combination with CAR-T cells
  Richard Vile, PhD, Mayo Clinic
• Panel Discussion

Break
2:10 – 2:20 p.m.  

CAR Integration and T Cell Malignancies
2:20 – 3:40 p.m.

• The biology and consequences of lentiviral integration: From HIV to engineered immune cells
  Frederic Bushman, University of Pennsylvania
• Incidence of secondary malignancies in patients receiving CAR-T for lymphoma
  Steven Schuster, MD, University of Pennsylvania
• Panel Discussion

Break
3:40 – 4:10 p.m. 

Oral Abstract Presentations
CAR T Clinical Translation and Correlatives
4:10 – 5:25 p.m.

• 1. Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (HuCART-meso) Administered in Combination with VCN-01 in Patients with Pancreatic and Serous Epithelial Ovarian Cancer 
  Janos Tanyi, University of Pennsylvania
• ​2. Combining CAR T Cell Therapy with Targeted Proton Beam Radiotherapy 
  Ugur Uslu, PhD, University of Pennsylvania 
• 14. Engineering Allogeneic Cell Immunotherapies in a Single Intervention with the Innovative Pin-pointTM Base Editing Platform 
  Shannon Hinsdale, Revvity
• 4. Precision Biomaterials-Mediated Chronic Stimulation Sustains Supernumerary Expansion of Human CAR-T Cells In Vitro 
  Xiao Huang, Drexel University 
• 5. Single Cell Analysis of Longitudinal CSF from Glioblastoma Patients Post Intrathecally Delivered EGFR-IL13Rα2 CAR T Therapy 
  Dana Silverbush, PhD, University of Pennsylvania School of Medicine 

Poster Viewing, Exhibits, and Networking Reception
5:30 – 6:45 p.m. 

Thursday, Oct. 17

Off the Shelf CAR-T Cells Using Direct In Vivo
8:30 – 10:15 a.m. 

• Engineering G proteins on lentiviral vectors for T cell-targeted in vivo delivery of CAR constructs
  Stephen Russell, MD, PhD, Vyriad 
• In Vivo Engineering of Human Immune Cells
  Tim Culp, PhD, Interius Biotherapeutics 
• Direct in vivo gene transfer
  Haig Aghajanian, PhD, Capstan 
• Panel Discussion

Break
10:15 -10:45 a.m.

Oral Abstract Presentations
Novel Targets and Effector Cells
10:45 a.m. – 12 p.m. 

• 6. Tracking CARs; Cell Surface Barcoding Novel Multi-targeted CAR T Cell Therapies for High Grade Gliomas 
  Ryan Cross, PhD, Walter and Eliza Hall Institute of Medical Research Immunology Division 
• 7. The Augmentation of Smac Levels through an Armed Vesicular Stomatitis Virus Enhances Antitumor Immunity by Triggering PANoptosis
  Yong Teng, PhD, Emory University School of Medicine
• 8. ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications 
  Shon Green, Adicet Therapeutics 
• 9. Bioreducible LiPBAE miR-590-3p NanomiRs Inhibit Recurrent Glioblastoma Growth and Prolongs Survival 
  Hernando Lopez-Bertoni, PhD, Johns Hopkins School of Medicine 
• 10. Tumor Associated Mitochondria Antigens (TAMAs) Vaccine Is Effective on Tumor and Tumor Associated Endothelial Cells: From the Mechanisms to the Clinical Validation 
  Francesca Costabile, PhD, University of Pennsylvania 

Closing Remarks
12 – 12:10 p.m. 

Ready to Register?

Register now!

Thank You to the Organizing Committee

• Chair: Saar Gill, MD, PhD
  University of Pennsylvania
• Hans-Peter Kiem, MD, PhD
  Fred Hutch
• Rayne Rouce, MD
  Baylor College of Medicine
• Paula Cannon, PhD
  University of Southern California
• Phillip Gregory, DPhil
  Regeneron Cell Medicines
• Chiara Bonini, MD
  Università Vita Salute San Raffaele
• Isabelle Riviere, PhD
  Takeda Therapeutics